Last reviewed · How we verify

DOR/ISL — Competitive Intelligence Brief

DOR/ISL (DOR/ISL) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fixed-dose combination of carbonic anhydrase inhibitor and prostaglandin analog. Area: Ophthalmology.

phase 3 Fixed-dose combination of carbonic anhydrase inhibitor and prostaglandin analog Carbonic anhydrase II; Prostaglandin F receptor (FP receptor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

DOR/ISL (DOR/ISL) — Merck Sharp & Dohme LLC. DOR/ISL is a combination of dorzolamide (a carbonic anhydrase inhibitor) and islatamide (a prostaglandin analog) that reduces intraocular pressure through dual mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DOR/ISL TARGET DOR/ISL Merck Sharp & Dohme LLC phase 3 Fixed-dose combination of carbonic anhydrase inhibitor and prostaglandin analog Carbonic anhydrase II; Prostaglandin F receptor (FP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fixed-dose combination of carbonic anhydrase inhibitor and prostaglandin analog class)

  1. Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DOR/ISL — Competitive Intelligence Brief. https://druglandscape.com/ci/dor-isl. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: